Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- REPL
- Price
- 7.90
- Stock movement up
- +0.21 (2.03%)
- Company name
- Replimune Group Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 826.01M
- Ent value
- 849.82M
- Price/Sales
- 204.36
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -22.29%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
REPL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 204.36 |
| Price to Book | - |
| EV to Sales | 210.25 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 78.44M |
| EPS (TTM) | -3.38 |
| FCF per share (TTM) | -2.93 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.47M |
| Gross profit (TTM) | -3.51M |
| Operating income (TTM) | -320.61M |
| Net income (TTM) | -310.26M |
| EPS (TTM) | -3.38 |
| EPS (1y forward) | -2.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -238.65% |
| Operating margin (TTM) | -21780.64% |
| Profit margin (TTM) | -21077.65% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 102.30M |
| Net receivables | 1.81M |
| Total current assets | 333.75M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 67.11M |
| Total assets | 389.45M |
| Accounts payable | 6.40M |
| Short/Current long term debt | 76.32M |
| Total current liabilities | 52.90M |
| Total liabilities | 126.11M |
| Shareholder's equity | 263.34M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -262.67M |
| Capital expenditures (TTM) | 7.02M |
| Free cash flow (TTM) | -269.69M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -117.82% |
| Return on Assets | -79.67% |
| Return on Invested Capital | -98.62% |
| Cash Return on Invested Capital | -85.73% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 10.18 |
| Daily high | 10.56 |
| Daily low | 10.03 |
| Daily Volume | 1.28M |
| All-time high | 52.65 |
| 1y analyst estimate | 12.57 |
| Beta | 0.67 |
| EPS (TTM) | -3.38 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Feb 2026 |
Downside potential
Loading...
Downside potential data
| REPL | S&P500 | |
| Current price drop from All-time high | -85.00% | -0.89% |
| Highest price drop | -94.67% | -19.00% |
| Date of highest drop | 22 Jul 2025 | 8 Apr 2025 |
| Avg drop from high | -81.89% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 290 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
826.01M
Marketcap category
Small-cap
Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Employees
479
Website
Investor relations
-
SEC filings
CEO
Philip Astley-Sparke
Country
USA
City
Woburn
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page